fashion -WSS

fashion

author：fashion 2025-08-26 23:45:54 - browse：113

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： How are insurers handling Leqembi and related scans?

WSS

PhRMA lawsuit over Medicare drug price negotiation tossed

BioAge raises $170M for combination therapy with Zepbound

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Gilead might be held responsible for not developing a drug

After half a century, Israel moves to evict squatter from his cave home on the beach

How digital tools helped lower hypertension in marginalized patients

knowledge

fashion

leisure time

Virginia high school admissions case could be legal follow

PhRMA lawsuit over Medicare drug price negotiation tossed

As demand for Covid shots wanes, Moderna seeks its next success

Blinken talks high

In age of alternative facts, a scholarly course on calling out crap

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medical leaders decry Supreme Court decision on affirmative action

Biogen Alzheimer’s drug launch off to slow start

In Memoriam: Notable people who died in 2023

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

focus

Private equity deals in Medicare Advantage declines

Blinken talks high

Vermont grapples with historic flooding as more rainstorms head for Northeast

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Vaccine advisory panel ACIP left half staffed by HHS

knowledge

hotspot

hotspot

leisure time